Shares Magazine
16.13p-0.13 (-0.77%)21 Nov 2024, 16:20
Jump to:
Creo Medical Group PLC Fundamentals
| Company Name | Creo Medical Group PLC | Last Updated | 2024-11-21 |
|---|---|---|---|
| Industry | Medical Devices | Sector | Healthcare |
| Shares in Issue | 361.780 m | Market Cap | £58.34 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.07 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.2049 | Debt Equity Ratio | 0.2257 |
| Asset Equity Ratio | 1.4620 | Cash Equity Ratio | 0.2068 |
| Quick Ratio | 1.9899 | Current Ratio | 3.24 |
| Price To Book Value | 1.4130 | ROCE | 0 |
Creo Medical Group PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Creo Medical Group PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £9.10 m | £10.20 m | £8.60 m |
| Intangible Assets | £26.20 m | £27.60 m | £35.95 m |
| Investments | £2.10 m | £2.10 m | £1.73 m |
| Total Fixed Assets | £38.70 m | £41.60 m | £39.44 m |
| Stocks | £8.10 m | £9.30 m | £8.50 m |
| Debtors | £7.90 m | £5.60 m | £4.46 m |
| Cash & Equivalents | £18.50 m | £13.10 m | £43.53 m |
| Other Assets | £1.30 m | £1.70 m | -£6.84 m |
| Total Assets | £76.60 m | £75.20 m | £100.61 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £9.90 m | £17.40 m | £19.74 m |
| Creditors after 1 year | £6.90 m | £8.50 m | £7.55 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £16.80 m | £25.90 m | £27.29 m |
| Net assets | £59.80 m | £49.30 m | £73.32 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £400,000.00 | £200,000.00 | £181,000.00 |
| Share Premium | £180.90 m | £149.50 m | £149.45 m |
| Profit / Loss | -£24.50 m | -£30.90 m | -£30.34 m |
| Other Equity | £59.80 m | £49.30 m | £73.32 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £59.80 m | £49.30 m | £73.32 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.08 | £0.11 | £0.07 |
| Debt-to-Equity | £0.09 | £0.12 | £0.07 |
| Assets / Equity | 1.4620 | 1.4620 | 1.4620 |
| Cash / Equity | 0.2068 | 0.2068 | 0.2068 |
| EPS | -£0.07 | -£0.14 | -£0.14 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£21.60 m | -£24.90 m | -£26.01 m |
| Cashflow before financing | £8.20 m | -£24.50 m | £5.98 m |
| Increase in Cash | -£10.10 m | -£30.50 m | -£1.86 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £30.80 m | £27.20 m | £25.16 m |
| Cost of sales | £15.50 m | £14.00 m | £13.58 m |
| Gross Profit | £15.30 m | £13.20 m | £11.59 m |
| Operating Profit | -£24.80 m | -£30.70 m | -£29.91 m |
| Pre-Tax profit | -£24.50 m | -£30.90 m | -£30.34 m |
Creo Medical Group PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from Europe and the rest from the United Kingdom and the rest of the world. |
| Latest Interim Date | 30 Sep 2024 |
| Latest Fiscal Year End Date | 15 May 2024 |
Creo Medical Group PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-05-21 | Mr. John Bradshaw | Non-Executive Director,Senior Independent Non-Executive Director |
| 2024-06-28 | Dr. Charles Alexander Evan Spicer | Non-Executive Director,Chairman |
| 2024-08-06 | Mr. Craig Jonathan Gulliford | Executive Director,Chief Executive Officer |
| 2024-10-24 | Mr. Richard John Rees | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-08-06 | Professor Christopher Paul Hancock | Executive Director,Chief Technology Officer |
| 2024-05-21 | Mr. David Gerard Woods | Executive Director,Chief Commercial Officer |
| 2024-10-21 | Mr. Kevin Timothy Crofton | Non-Executive Director,Chairman |
| 2024-05-21 | Ms. Ivonne Maria Gloria Cantu | Non-Executive Director |
Creo Medical Group PLC Contact Details
| Company Name | Creo Medical Group PLC |
|---|---|
| Address | Beaufort Park Way, Unit 2, Creo House, Chepstow, NP16 5UH |
| Telephone | +44 1291606005 |
| Website | https://www.creomedical.com |
Creo Medical Group PLC Advisors
| Solicitor | Taylor Wessing LLP |
|---|---|
| Phone | +44 2073007000 |
| Fax | +44 2073007100 |
| Auditor | KPMG |
|---|---|
| Phone | +44 01179054000 |
| Fax | +44 01179054001 |
| Registrar | Equiniti Limited |
|---|---|
| Phone | +44 3713842030 |
| Fax | +44 3713842100 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Stockbroker | Cenkos Securities |
|---|---|
| Phone | +44 2073978900 |
| Fax | +44 2073978901 |
| Nominated Adviser | Cenkos Securities |
|---|---|
| Phone | +44 2073978900 |
| Fax | +44 2073978901 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
